Glucotrack (GCTK, Financial) has announced its participation in the FORGETDIABETES initiative, a project poised to develop a revolutionary bionic pancreas. This groundbreaking technology aims to provide automated, long-term insulin delivery, minimizing the need for patient intervention and significantly improving glucose control for individuals with type 1 diabetes.
Funded by the European Union's Horizon 2020 program, which allocates EUR 75 billion towards research and innovation, the FORGETDIABETES initiative is focused on creating an "invisible" pancreas. This development is expected to lift the psychological and therapeutic burdens associated with current diabetes management techniques. Glucotrack's role involves the integration of its Continuous Blood Glucose Monitor, offering real-time glucose data to facilitate precise insulin delivery by the bionic pancreas.
Despite advancements in diabetes management, such as the use of continuous glucose sensors and insulin pumps, the daily demands of the condition remain a significant challenge. The bionic pancreas project aims to address these issues by transforming diabetes care into a more manageable aspect of life, akin to the use of long-term contact lenses. By simplifying the process, the innovative system could vastly improve the quality of life for many, allowing patients to engage more fully in daily activities without incessant disruptions related to traditional diabetes management.
